Best evidence in critical care medicine: The use of recombinant human erythropoietin to reduce red cell transfusions in critically ill patients

Osama Almuslim, David Leasa

Open source

DOI
10.1007/bf03018406
Published
2004-06
Container
Canadian Journal of Anesthesia/Journal canadien d'anesthésie
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/bf03018406,
  title = {Best evidence in critical care medicine: The use of recombinant human erythropoietin to reduce red cell transfusions in critically ill patients},
  author = {Osama Almuslim and David Leasa},
  year = {2004},
  journal = {Canadian Journal of Anesthesia/Journal canadien d'anesthésie},
  doi = {10.1007/bf03018406},
  url = {https://doi.org/10.1007/bf03018406}
}

RIS

TY  - JOUR
TI  - Best evidence in critical care medicine: The use of recombinant human erythropoietin to reduce red cell transfusions in critically ill patients
AU  - Osama Almuslim
AU  - David Leasa
PY  - 2004
JO  - Canadian Journal of Anesthesia/Journal canadien d'anesthésie
DO  - 10.1007/bf03018406
UR  - https://doi.org/10.1007/bf03018406
ER  - 

APA

Almuslim, O., & Leasa, D. (2004). Best evidence in critical care medicine: The use of recombinant human erythropoietin to reduce red cell transfusions in critically ill patients. Canadian Journal of Anesthesia/Journal canadien d'anesthésie. https://doi.org/10.1007/bf03018406

Source records